Zydus Lifesciences (Large Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Zydus Lifesciences Limited |
|||
|
Price: ₹985.90 (-0.96%) | ||
| 52 Week Low: ₹706.60 52 Week High: ₹1,324.30 |
|||
| Market Capital: 1,08,270.34 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Zydus Lifesciences Share Price Target For 2025
- 1.1.1: Zydus Lifesciences Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Zydus Lifesciences Share Price Target For 2026
- 1.2.1: Zydus Lifesciences Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Zydus Lifesciences Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Zydus Lifesciences Brief Company Overview
- 4: Zydus Lifesciences Financial Performance
- 4.0.1: Is Zydus Lifesciences A Good Buy For Long Term?
Zydus Lifesciences, a Large Cap company in the Drug Manufacturers - Specialty & Generic Industry has delivered 289.1% returns in 5-year showing 18.6% quarterly revenue growth with 19.7% profit margin, making it a potential Multibagger.
To predict the Zydus Lifesciences's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Zydus Lifesciences Share Price Target For 2025
The line chart displays the monthly closing prices of Zydus Lifesciences with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Zydus Lifesciences shares in 2025, see the table below.
Zydus Lifesciences Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 1069.95 (+8.52%) | Price Action: 26 Sep 2024 High |
| 2025 Target 2 | 1059.0 (+7.41%) | Price Action: 08 Oct 2024 High |
| 2025 Target 1 | 1048.24 (+6.32%) | Price Action: 29 May 2024 High |
| Current Price | 985.90 | Zydus Lifesciences's share price as of 21 Jan 2025 |
| Stop Loss 1 | 956.56 (-2.98%) | Price Action: 24 Apr 2024 High |
| Stop Loss 2 | 946.85 (-3.97%) | Price Action: 13 Nov 2024 Low |
| Stop Loss 3 | 936.96 (-4.97%) | Price Action: 05 Mar 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Zydus Lifesciences is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹981.15 serves as the nearest technical reference point.
Historical Returns: 3-month: -1.53% | 6-month: -20.95% | 1-year: +29.91%
Zydus Lifesciences Share Price Target For 2026
The line chart displays the monthly closing prices of Zydus Lifesciences with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Zydus Lifesciences shares in 2026, see the table below.
Zydus Lifesciences Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 1581.73 (+60.43%) | Price Action: Chart |
| 2026 Target 2 | 1552.24 (+57.44%) | Fibonacci Extension Level 64.90% |
| 2026 Target 1 | 1530.24 (+55.21%) | Fibonacci Extension Level 123.60% |
| Current Price | 985.90 | Zydus Lifesciences's share price as of 21 Jan 2025 |
| Stop Loss 1 | 842.75 (-14.52%) | Price Action: 13 Feb 2024 Low |
| Stop Loss 2 | 834.32 (-15.38%) | Price Action: Chart |
| Stop Loss 3 | 818.91 (-16.94%) | Price Action: 09 Feb 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: Zydus Lifesciences is currently trading at 45.2% of its 52-week range (₹706.6 - ₹1324.3).
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +29.91% | 3-year: +149.57% | 5-year: +289.05%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Zydus Lifesciences Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹985.90 | ||
| 2025 | ₹1,556.34 | +57.85% | ₹1,579.69 |
| 2026 | ₹2,053.54 | +31.94% | ₹2,084.34 |
| 2027 | ₹2,678.11 | +30.41% | ₹2,718.28 |
| 2028 | ₹3,100.17 | +15.75% | ₹3,146.67 |
| 2029 | ₹3,517.14 | +13.44% | ₹3,569.90 |
| 2030 | ₹4,519.24 | +28.49% | ₹4,587.03 |
| 2031 | ₹5,117.91 | +13.24% | ₹5,194.68 |
| 2032 | ₹6,416.18 | +25.36% | ₹6,512.42 |
| 2033 | ₹8,059.79 | +25.61% | ₹8,180.69 |
| 2034 | ₹9,813.04 | +21.75% | ₹9,960.24 |
| 2035 | ₹11,194.76 | +14.08% | ₹11,362.68 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Zydus Lifesciences Brief Company Overview
Zydus Lifesciences Limited: A Leading Pharmaceutical Company Established in 1952, Zydus Lifesciences Limited is a renowned pharmaceutical company based in Ahmedabad, India. It operates in India, the United States, and internationally. Diverse Product Range Finished dosage...
human formulations: Generics, branded generics, specialty formulations (biosimilars, vaccines) Active pharmaceutical ingredients Consumer wellness products Biological products: Oncology, autoimmune disease, hepatology Zydus Lifesciences offers its products under well-known brands like Everyuth, Nutralite, Complan, Glucon D, and Nycil. Reputation and Commitment Zydus Lifesciences is highly reputed in the industry for its research, development, and commitment to providing affordable healthcare solutions.Zydus Lifesciences Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 1,08,270.34 Crore | Market valuation of Zydus Lifesciences's shares. |
| Revenue (TTM) | 19,547.39 Crore | Total revenue generated by Zydus Lifesciences over the past twelve months. |
| Net Income (TTM) | +3,836.49 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +25.65% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +19.73% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+18.6% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+298.6% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
3.63 | Company's total debt divided by total shareholder equity. |
| Total Debt | 804.19 Crore | Sum of Zydus Lifesciences's current & long-term financial obligations. |
| Total Cash | 1,357.59 Crore | Total amount of liquid funds available to Zydus Lifesciences. |
| Beta | 0.55 | Beta is less than 1 indicating that the Zydus Lifesciences's price is less volatile than the market. |
Is Zydus Lifesciences A Good Buy For Long Term?
Zydus Lifesciences, a large-cap stock with robust revenue and profit growth in the last year, exhibits long-term investment potential. Its high profit margin of 19.74% and consistent returns over the past 12 months (106.96%) suggest its stability and growth prospects. The company's strong financial position, with a healthy cash balance and manageable debt, further supports its long-term viability. As such, it's a compelling option for long-term investors seeking a balance between growth and stability.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
